X4 Pharmaceuticals Appoints Michael Wyzga as Chair of Board of Directors
Jul. 12, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 12, 2018--X4 Pharmaceuticals, a clinical-stage biotechnology company developing novel CXCR4 allosteric antagonist drug candidates designed to improve immune cell trafficking to treat rare diseases and cancer, today announced the appointment of Michael Wyzga as the Chair of the company’s Board of Directors. Mr. Wyzga is an accomplished biopharmaceutical industry leader with decades of strategic, management and operational experience at companies at many stages of growth, including companies focused on rare diseases and cancer.
From 1998 to 2011, Mr. Wyzga held various senior leadership positions at Genzyme Corporation, a global biotechnology company, including serving as its Executive Vice President, Finance and Chief Financial Officer. Between December 2011 and November 2013, Mr. Wyzga served as President and Chief Executive Officer and a member of the Board of Directors of Radius Health, a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and women’s health conditions. Currently, Mr. Wyzga is the CEO and President of MSW Consulting Inc. Additionally, Mr. Wyzga serves on the Board of Directors for several biopharmaceutical companies, including Akebia Therapeutics, Inc., Exact Sciences Corporation, and GenSight Biologics . Mr. Wyzga received a BS from Suffolk University and an MBA from Providence College.
"Mike Wyzga is a distinguished leader in the biotech community. He brings the perspectives of his 30 years of industry experience founded in the delivery life-changing therapies for patients across the world. Additionally, Mike brings a strong understanding of corporate governance and management, as well as deep strategic, finance and operational experience that will support X4 in this rapidly growing stage of the company,” said Paula Ragan, PhD, President and CEO of X4. “We are very pleased to have him join X4 Pharmaceuticals as the Chair of our Board of Directors.”
“X4 is developing novel therapeutics that have shown promising clinical data in two important therapeutic areas, rare diseases and cancer,” said Mr. Wyzga. “X4 has made impressive achievements to date with its pipeline of drug candidates, and I look forward to contributing to the company’s continued success in developing needed therapies for patients.”
About X4 Pharmaceuticals X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases and cancer. The Company’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4’s most advanced product candidate is in a Phase 2/3 clinical trial in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease and is currently under investigation in multiple clinical trials in solid tumors. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA. For more information, visit www.x4pharma.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180712005214/en/
CONTACT: X4 Pharmaceuticals
Kathryn Morris, 914-204-6412
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL
SOURCE: X4 Pharmaceuticals
Copyright Business Wire 2018.
PUB: 07/12/2018 08:00 AM/DISC: 07/12/2018 08:01 AM